quinazolines has been researched along with Arteriosclerosis, Coronary in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ballantyne, CM; Barter, PJ; Borgman, M; Brewer, HB; Herrman, JP; Hu, B; Kastelein, JJ; Kataoka, Y; Merkely, B; Nicholls, SJ; Nissen, SE; Puri, R; Uno, K; Wolski, K | 1 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Davidson, MH | 1 |
| Ballantyne, CM; Borgman, M; Gordon, A; Johansson, J; Kastelein, JJ; Nicholls, SJ; Nissen, SE; Taylor, A; Wolski, K | 1 |
| Shah, PK | 1 |
| Ballantyne, CM; Barter, PJ; Borgman, MR; Brewer, HB; Gordon, A; Johannson, J; Kastelein, JJ; Nicholls, SJ; Nissen, SE; Wong, NC | 1 |
| Ching, LC; Kou, YR; Lee, HF; Lee, TS; Shyue, SK; Wei, J; Zhao, JF | 1 |
3 trial(s) available for quinazolines and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.
Topics: Aged; Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Double-Blind Method; Female; Humans; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Quinazolines; Quinazolinones | 2016 |
Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial.
Topics: Aged; Apolipoprotein A-I; Cholesterol, HDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prospective Studies; Quinazolines; Quinazolinones; Treatment Outcome | 2011 |
ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.
Topics: Adolescent; Apolipoprotein A-I; Cardiotonic Agents; Cholesterol, HDL; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Female; Follow-Up Studies; Humans; Male; Plaque, Atherosclerotic; Quinazolines; Quinazolinones; Ultrasonography | 2012 |
4 other study(ies) available for quinazolines and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Apolipoprotein A-I therapy promise, challenges, and disappointment.
Topics: Apolipoprotein A-I; Cholesterol, HDL; Coronary Artery Disease; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Quinazolines; Quinazolinones; Treatment Outcome | 2011 |
Atherosclerosis: targeting endogenous apo A-I--a new approach for raising HDL.
Topics: Apolipoprotein A-I; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Quinazolines; Quinazolinones; Risk Factors | 2011 |
Essential role of transient receptor potential vanilloid type 1 in evodiamine-mediated protection against atherosclerosis.
Topics: Animals; Apolipoproteins E; Blotting, Western; Coronary Artery Disease; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fatty Liver; Hyperlipidemias; Male; Mice; Mice, Knockout; Quinazolines; TRPV Cation Channels | 2013 |